Harvard Bioscience, Inc. (HBIO) Stock

Harvard Bioscience, Inc. (HBIO) is a Technology stock trading at $5.89 (as of 2026-06-18), with a market capitalization of $26.48M and a trailing P/E of -6.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Harvard Bioscience develops, manufactures, and sells laboratory technologies and instrumentation used in fundamental research, discovery, and pre-clinical testing for drug development. Its products include cellular and molecular instruments, tissue and organ-based research equipment, spectrophotometers and related analytical devices, as well as precision measuring systems and preclinical products sold to research organizations and institutions.

Valuation — source: SEC EDGAR (first-party)
Price	$5.89
Market Cap	$26.48M
P/E Ratio	-6.5
EV / EBITDA	33.7
Price / Book	2.64
Price / Sales	0.31
DCF Value (model)	$2.48
DCF Upside vs Price	-57.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$86.55M
Net Margin	-65.5%
Return on Equity	-97.4%
Debt / Equity	3.60
Current Ratio	1.99
Revenue Growth (YoY)	-4.7%
EPS Growth (YoY)	-32.5%
FCF Growth (YoY)	-144.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.90 (distress)
Piotroski F-Score	4/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-6.5
Sector P/E (Technology)	32.6
Industry P/E (Measuring & Control Equipment)	60.1
vs Sector	-119.8%
vs Industry	-110.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	WEBER CAPITAL MANAGEMENT LLC /ADV ($2.14M)
Institutional Holders Tracked	10

Company
Sector	Technology
Industry	Measuring & Control Equipment
CEO	John Duke
Employees	330
Country	US
IPO Date	2001-03-19

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.